Prevalence, incidence and clinical outcome of hepatitis B virus and hepatitis C virus hepatitis in patients undergoing allogeneic hematopoietic stem cell transplantation between 2001 and 2004.
The prevalence, incidence and clinical course of viral hepatitis were prospectively determined in consecutive recipients of T-cell depleted hematopoieic stem cell transplants (49 mismatched, 60 matched, mean age 38 years; range 11-65). The prevalence of hepatitis B virus (HBV) was 15.6% and that of hepatitis C virus was 3.7% (HCV). HBV reactivated in one patient. Another developed ex novo acute hepatitis B which progressed to chronic hepatitis. There were no new cases of hepatitis C or worsening of pre-transplant HCV infections. HBV and HBC did not affect the outcome of T-cell depleted hematopoieic stem cell transplantation. Surveillance is important given the risk of HCV and HBV infection and/or reactivation and the efficacy of the new anti-hepatitis drugs.
Francisci
Daniela
D
Division of Infectious Diseases, Department of Experimental Medicine and Biochemical Science, University of Perugia, Ospedale R. Silvestrini, Sant'Andrea delle Fratte, 06156, Perugia, Italy. francisd@unipg.it
Aversa
Franco
F
Coricelli
Vittoria
V
Carotti
Alessandra
A
Canovari
Benedetta
B
Falcinelli
Flavio
F
Belfiori
Barbara
B
Aloisi
Teresa
T
Baldelli
Franco
F
Martelli
Massimo Fabrizio
MF
Stagni
Giuliano
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006509:Hepatitis B / Q000209:etiology*; D006526:Hepatitis C / Q000209:etiology*; D006648:Histocompatibility; D006801:Humans; D015994:Incidence; D008212:Lymphocyte Depletion; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome